Edwards Lifesciences Share Holder Equity 2010-2022 | EW

Edwards Lifesciences share holder equity from 2010 to 2022. Share holder equity can be defined as the sum of preferred and common equity items
  • Edwards Lifesciences share holder equity for the quarter ending December 31, 2022 was $5.807B, a 0.5% decline year-over-year.
  • Edwards Lifesciences share holder equity for 2022 was $5.807B, a 0.5% decline from 2021.
  • Edwards Lifesciences share holder equity for 2021 was $5.836B, a 27.58% increase from 2020.
  • Edwards Lifesciences share holder equity for 2020 was $4.574B, a 10.27% increase from 2019.
Edwards Lifesciences Annual Share Holder Equity
(Millions of US $)
2022 $5,807
2021 $5,836
2020 $4,574
2019 $4,148
2018 $3,140
2017 $2,956
2016 $2,619
2015 $2,503
2014 $2,191
2013 $1,544
2012 $1,479
2011 $1,338
2010 $1,308
2009 $1,158
Edwards Lifesciences Quarterly Share Holder Equity
(Millions of US $)
2022-12-31 $5,807
2022-09-30 $6,218
2022-06-30 $5,944
2022-03-31 $5,845
2021-12-31 $5,836
2021-09-30 $5,541
2021-06-30 $5,133
2021-03-31 $4,658
2020-12-31 $4,574
2020-09-30 $4,210
2020-06-30 $3,839
2020-03-31 $3,901
2019-12-31 $4,148
2019-09-30 $3,815
2019-06-30 $3,500
2019-03-31 $3,448
2018-12-31 $3,140
2018-09-30 $3,361
2018-06-30 $3,164
2018-03-31 $3,246
2017-12-31 $2,956
2017-09-30 $3,163
2017-06-30 $2,940
2017-03-31 $2,743
2016-12-31 $2,619
2016-09-30 $2,692
2016-06-30 $2,471
2016-03-31 $2,299
2015-12-31 $2,503
2015-09-30 $2,421
2015-06-30 $2,289
2015-03-31 $2,214
2014-12-31 $2,191
2014-09-30 $2,043
2014-06-30 $1,915
2014-03-31 $1,341
2013-12-31 $1,544
2013-09-30 $1,437
2013-06-30 $1,580
2013-03-31 $1,592
2012-12-31 $1,479
2012-09-30 $1,536
2012-06-30 $1,435
2012-03-31 $1,390
2011-12-31 $1,338
2011-09-30 $1,355
2011-06-30 $1,385
2011-03-31 $1,358
2010-12-31 $1,308
2010-09-30 $1,234
2010-06-30 $1,118
2010-03-31 $1,152
2009-12-31 $1,158
2009-09-30 $1,090
2009-06-30 $1,003
2009-03-31 $943
Sector Industry Market Cap Revenue
Medical Medical Instruments Manufacturing $49.143B $5.382B
Edwards Lifesciences Corporation deals in products and technologies aimed at treating advanced cardiovascular diseases, especially structural heart disease in critically ill patients. The company is the world's leading manufacturer of tissue heart valves and repair products used to replace or repair a patient's diseased or defective heart valve. Edwards is also a leading player in hemodynamic monitoring systems used to measure a patient's cardiovascular function in the hospital setting. The company's products and technologies are categorized into four main areas: Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), Surgical Structural Heart, and Critical Care.
Stock Name Country Market Cap PE Ratio
Thermo Fisher Scientific (TMO) United States $212.206B 23.69
Alcon (ALC) Switzerland $32.311B 29.57
STERIS (STE) Ireland $17.996B 22.80
Fresenius Medical Care AG KGaA (FMS) Germany $11.408B 11.93
Teleflex (TFX) United States $11.141B 18.17
Penumbra (PEN) United States $10.162B 1565.71
Globus Medical (GMED) United States $5.255B 25.31
Integer Holdings (ITGR) United States $2.448B 18.98
Glaukos (GKOS) United States $2.324B 0.00
Paragon 28 (FNA) United States $1.527B 0.00
AVANOS MEDICAL, INC (AVNS) United States $1.330B 17.30
Nevro (NVRO) United States $1.089B 0.00
Artivion (AORT) United States $0.488B 240.60